Skip to content

Efficacy of Compound Qingdai Capsules in the Treatment of Moderate-to-Severe Psoriasis and Its Effects on Immune-Inflammatory and Angiogenic Markers: A Randomized Controlled Clinical Study

Efficacy of Compound Qingdai Capsules in the Treatment of Moderate-to-Severe Psoriasis and Its Effects on Immune-Inflammatory and Angiogenic Markers: A Randomized Controlled Clinical Study

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600121671
Enrollment
Unknown
Registered
2026-04-01
Start date
2026-04-01
Completion date
Unknown
Last updated
2026-04-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Psoriasis

Interventions

Compound Qingdai Capsule intervention group:Compound Qingdai Capsules, 4 capsules each time, 3 times a day.
Blank control group:Observe patient symptoms only, without intervention

Sponsors

Gong An County People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Age 18-70 years (inclusive), no gender restriction; 2. Clinically diagnosed with moderate to severe plaque psoriasis, with severity defined according to the "Chinese Psoriasis Diagnosis and Treatment Guidelines (2023 Edition)": PASI = 3, BSA = 3%, or DLQI = 6; 3. No clinically significant active infection; 4. No systemic treatment in the past 2 months; 5. Willing to follow medical advice and take medication regularly for at least 12 weeks, attend regular follow-ups, and have complete clinical basic information and medical records.

Exclusion criteria

Exclusion criteria: 1.Patients with active tuberculosis, active hepatitis B virus infection, human immunodeficiency virus (HIV) infection, severe bacterial infections, or other severely immunocompromised conditions; patients with concurrent severe diseases of vital organs and tissues (e.g., heart, brain, lungs, liver, kidneys); patients with severe hepatic or renal impairment; or patients with concurrent malignancies; 2. Female patients who are pregnant, breastfeeding, or planning to become pregnant in the near future; 3.Patients allergic to or intolerant of Compound Qingdai Capsules; 4.Other conditions that, in the opinion of the investigator, make the patient unsuitable to participate in this clinical study.

Design outcomes

Primary

MeasureTime frame
Psoriasis Area and Severity Index (PASI) score;

Secondary

MeasureTime frame
Affected body surface area (BSA);Physician Global Assessment (PGA);Dermatology Life Quality Index (DLQI);Scalp Psoriasis Severity Index (PSSI);Modified Nail Psoriasis Severity Index (mNAPSI);Static Physician’s Global Assessment of Genitalia (sPGA-G);Weight;Blood Pressure;Waist circumference;

Countries

China

Contacts

Public ContactJinfang Chen

Gong An County People's Hospital

77422205@qq.com+86 159 2659 1804

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Apr 17, 2026